Table 2 Demographics, comorbidities, and clinical parameters of survivors and non-survivors
Parameters | Surviving (n = 113) | Non-surviving (n = 40) | P value |
|---|---|---|---|
Male gender, n (%) | 74 (65.5) | 34 (85%) | 0.0256 |
Age, mean ± SD (y) | 61.7 ± 15.1 | 68.9 ± 16.6 | 0.0162 |
BMI, mean ± SD (kg/m2) | 20.2 ± 4.3 | 21.6 ± 4.1 | 0.0831 |
Body temperature | 37.3 ± 1.7 | 38.4 ± 1.3 | 0.00465 |
Underlying pneumonia (bacterial/aspiration /VAPa) | 42/34/3 | 15/9/1 | 0.922 |
Comorbidity | |||
chronic heart disease | 26% | 18% | 0.29 |
chronic respiratory disease | 21% | 20% | 0.98 |
chronic kidney disease | 20% | 20% | 1.00 |
glucose intolerance | 22% | 25% | 0.83 |
connective tissue disease | 8% | 13% | 0.52 |
Direct lung injury | 81% | 80% | 1.00 |
Berlin definition severity | |||
mild | 38 | 4 | |
moderate | 56 | 15 | < 0.001 |
severe | 19 | 21 | |
Sepsis | 70% | 55% | 0.12 |
Use of catecholamine | 42% | 25% | 0.086 |
Clinical scores | |||
APACHE II score | 23 ± 7 | 28 ± 7 | < 0.001 |
SOFA score | 10 ± 3 | 13 ± 4 | < 0.001 |
SAPS II score | 58 ± 14 | 68 ± 14 | < 0.001 |
Laboratory data | |||
White blood cell (×103/mm3) | 14.0 ± 7.9 | 13.9 ± 13.3 | 0.95 |
Platelet (× 103/mm3) | 208 ± 154 | 152 ± 106 | 0.035 |
Total bililubin (mg/dL) | 2.0 ± 4.9 | 2.1 ± 4.8 | 0.957 |
Creatinine (mg/dL) | 1.4 ± 1.2 | 2.0 ± 1.9 | 0.035 |
C-reactive protein (mg/dL) | 12.1 ± 9.8 | 12.9 ± 12.3 | 0.659 |
LDH (IU/L) | 377 ± 228 | 324 ± 133 | 0.163 |
HCO3- (mEq/L) | 25.9 ± 7.9 | 24.3 ± 9.8 | 0.29 |
PaCO2 (Torr) | 44.5 ± 15.8 | 48.2 ± 16.9 | 0.216 |
Lactate (mmol/L) | 2.4 ± 2.8 | 3.7 ± 3.1 | < 0.001 |
HRCT score | 175 ± 69 | 193 ± 71 | 0.182 |
Max inspiratory pressure (cmH2O) | 18 ± 7 | 23 ± 6 | < 0.001 |